


## BGC-20-1531 free base

<b>Cat. No.:</b>	HY-19849		
<b>CAS No.:</b>	736183-35-0		
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>24</sub> N <sub>2</sub> O <sub>6</sub> S		
<b>Molecular Weight:</b>	492.54		
<b>Target:</b>	Prostaglandin Receptor		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 250 mg/mL (507.57 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.0303 mL	10.1515 mL	20.3029 mL
		5 mM	0.4061 mL	2.0303 mL	4.0606 mL
10 mM		0.2030 mL	1.0151 mL	2.0303 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.22 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP <sub>4</sub> receptor antagonist, with a pK <sub>B</sub> of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	EP <sub>4</sub> 7.6 (pKd)
<b>In Vitro</b>	BGC-20-1531 free base competitively antagonized PGE <sub>2</sub> -induced vasodilatation of human middle cerebral (pK <sub>B</sub> =7.8) and meningeal (pK <sub>B</sub> =7.6) arteries, but had no effect on responses induced by PGE <sub>2</sub> on coronary, pulmonary or renal arteries <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE <sub>2</sub> -induced increase in canine carotid blood flow <sup>[1]</sup> .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Beagle dogs <sup>[1]</sup>
Dosage:	1-10 mg/kg
Administration:	I.v.
Result:	Caused a dose-dependent antagonism of the PGE <sub>2</sub> -induced increase in canine carotid blood flow.

## REFERENCES

[1]. Maubach KA, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009;156(2):316-327.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA